| triglyceride homeostasis |
phenotype |
2 |
2 |
triglyceride regulation |
| triglyceride levels |
phenotype |
6 |
4 |
triglycerides |
| triglycerides |
phenotype |
19 |
16 |
TG, elevated triglycerides, fasting serum triglycerides, hepatic TG, hepatic triglycerides, liver triglycerides, plasma TG, plasma triglycerides, serum triglyceride, triglycerides |
| trios |
cohort |
8 |
6 |
trios |
| Tris-HCl |
drug |
18 |
6 |
Tris hydrochloride, Tris-HCl (pH 7.6), Tris–HCl |
| Tris-HCl buffer |
drug |
3 |
1 |
|
| Triton-X |
drug |
3 |
— |
Triton X-100 |
| Triton X-100 |
drug |
28 |
10 |
0.05% Triton, 0.1% Triton X-100, 0.25% Triton X-100, Triton, Tx-100 |
| Triton-X100 |
drug |
2 |
1 |
|
| Trizol |
drug |
11 |
5 |
Invitrogen Trizol, TRIzol, TRIzol reagent, TRIzol® reagent, Trizol (Life Technologies) |
| Trizol reagent |
drug |
7 |
5 |
Trizol |
| Trp53 |
gene |
9 |
4 |
p53 |
| TRPS1 |
gene |
2 |
1 |
|
| TrpV1 |
gene |
3 |
2 |
TrpV1, capsaicin receptor, transient receptor potential vanilloid type I channel, transient receptor potential vanilloid1 |
| truncating variant |
variant |
2 |
2 |
premature termination codon variants, truncating variants |
| trust |
phenotype |
2 |
1 |
|
| trypsin |
drug |
5 |
3 |
0.05% trypsin, 0.25% trypsin, bovine pancreatic trypsin |
| trypsin-EDTA |
drug |
3 |
— |
Trypsin/EDTA |
| Trypsin inhibitor |
drug |
4 |
2 |
T6522 |
| TS |
cohort |
5 |
10 |
Tourette syndrome |
